Cover Image
市場調查報告書

經導管主動脈瓣:醫療設備的開發平台分析

Transcatheter Aortic Valves (TAVI) - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 579816
出版日期 內容資訊 英文 174 Pages
訂單完成後即時交付
價格
Back to Top
經導管主動脈瓣:醫療設備的開發平台分析 Transcatheter Aortic Valves (TAVI) - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年11月07日 內容資訊: 英文 174 Pages
簡介

本報告提供經導管主動脈瓣的開發中產品的相關調查,提供產品開發·臨床實驗的整體進展,及企業·各產品詳細趨勢(臨床實驗的進展,開始/結束時期,核准預測等),總括性彙整近幾年的開發·資本交易趨勢等資訊。

第1章 目錄

第2章 簡介

  • 經導管主動脈瓣概要

第3章 經導管主動脈瓣-開發中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各核准機關
  • 開發中產品:各預定核准時期
  • 現在進行中的臨床實驗

第4章 經導管主動脈瓣-正在開發的開發中產品:各企業

  • 經導管主動脈瓣企業:各開發階段的開發中產品
  • 經導管主動脈瓣:各開發階段的開發中產品

第5章 經導管主動脈瓣:企業及產品概要

  • Admedus Ltd Company
    • 開發中產品及進行中的臨床實驗概要
  • Aegis Surgical Limited
  • Arbor Surgical Technologies, Inc.
  • Boston Scientific Corp
  • Clemson University
  • Colibri Heart Valve, LLC
  • Daidalos Solutions BV
  • Direct Flow Medical Inc
  • DSM Dyneema B.V.
  • Edwards Lifesciences Corp
  • Hansen Medical Inc
  • HLT, Inc.
  • JC Medical, Inc.
  • JenaValve Technology GmbH
  • Mayo Clinic US
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • MicroPort Scientific Corp
  • PolyNova Cardiovascular LLC
  • RegenaGraft
  • ReValve Med Inc
  • SAS Cormove
  • St. Jude Medical LLC
  • Symetis AG
  • Thubrikar Aortic Valve, Inc.
  • University College London
  • University of California San Francisco
  • University of Cambridge
  • University of Iowa
  • Vascular Concepts Ltd
  • Venus MedTech
  • Xeltis AG

第6章 經導管主動脈瓣:近幾年趨勢

第7章 附錄

  • 調查手法
  • 關於GlobalData
  • 聯絡處
  • 免責聲明

圖表清單

目錄
Product Code: GDME0497EPD

GlobalData's Medical Devices sector report, "Transcatheter Aortic Valves (TAVI) - Medical Devices Pipeline Assessment, 2017" provides an overview of Transcatheter Aortic Valves (TAVI) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Aortic Valves (TAVI) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Transcatheter Aortic Valves (TAVI) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transcatheter Aortic Valves (TAVI) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transcatheter Aortic Valves (TAVI) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Transcatheter Aortic Valves (TAVI) Overview 12

3 Products under Development 13

  • 3.1 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development 13
  • 3.2 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Territory 14
  • 3.3 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Regulatory Path 15
  • 3.4 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Estimated Approval Date 16
  • 3.5 Transcatheter Aortic Valves (TAVI) - Ongoing Clinical Trials 17

4 Transcatheter Aortic Valves (TAVI) - Pipeline Products under Development by Companies 18

  • 4.1 Transcatheter Aortic Valves (TAVI) Companies - Pipeline Products by Stage of Development 18
  • 4.2 Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development 20

5 Transcatheter Aortic Valves (TAVI) Companies and Product Overview 22

  • 5.1 Admedus Ltd Company Overview 22
    • 5.1.1 Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.2 Aegis Surgical Limited Company Overview 23
    • 5.2.1 Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.3 Arbor Surgical Technologies, Inc. Company Overview 24
    • 5.3.1 Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.4 Boston Scientific Corp Company Overview 25
    • 5.4.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.5 Clemson University Company Overview 55
    • 5.5.1 Clemson University Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.6 Colibri Heart Valve, LLC Company Overview 56
    • 5.6.1 Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.7 Daidalos Solutions BV Company Overview 61
    • 5.7.1 Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.8 Direct Flow Medical Inc Company Overview 62
    • 5.8.1 Direct Flow Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.9 DSM Dyneema B.V. Company Overview 66
    • 5.9.1 DSM Dyneema B.V. Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.10 Edwards Lifesciences Corp Company Overview 67
    • 5.10.1 Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.11 Hansen Medical Inc Company Overview 75
    • 5.11.1 Hansen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 75
  • 5.12 HLT, Inc. Company Overview 76
    • 5.12.1 HLT, Inc. Pipeline Products & Ongoing Clinical Trials Overview 76
  • 5.13 JC Medical, Inc. Company Overview 79
    • 5.13.1 JC Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 79
  • 5.14 JenaValve Technology GmbH Company Overview 82
    • 5.14.1 JenaValve Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 82
  • 5.15 Mayo Clinic US Company Overview 85
    • 5.15.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 85
  • 5.16 Medtronic plc Company Overview 86
    • 5.16.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 86
  • 5.17 Meril Life Sciences Pvt Ltd Company Overview 90
    • 5.17.1 Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 90
  • 5.18 MicroPort Scientific Corp Company Overview 91
    • 5.18.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 91
  • 5.19 PolyNova Cardiovascular LLC (Inactive) Company Overview 94
    • 5.19.1 PolyNova Cardiovascular LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 94
  • 5.20 RegenaGraft Company Overview 95
    • 5.20.1 RegenaGraft Pipeline Products & Ongoing Clinical Trials Overview 95
  • 5.21 ReValve Med Inc Company Overview 96
    • 5.21.1 ReValve Med Inc Pipeline Products & Ongoing Clinical Trials Overview 96
  • 5.22 SAS Cormove Company Overview 97
    • 5.22.1 SAS Cormove Pipeline Products & Ongoing Clinical Trials Overview 97
  • 5.23 St. Jude Medical LLC Company Overview 98
    • 5.23.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 98
  • 5.24 Symetis AG Company Overview 102
    • 5.24.1 Symetis AG Pipeline Products & Ongoing Clinical Trials Overview 102
  • 5.25 Thubrikar Aortic Valve, Inc. Company Overview 112
    • 5.25.1 Thubrikar Aortic Valve, Inc. Pipeline Products & Ongoing Clinical Trials Overview 112
  • 5.26 University College London Company Overview 113
    • 5.26.1 University College London Pipeline Products & Ongoing Clinical Trials Overview 113
  • 5.27 University of California San Francisco Company Overview 114
    • 5.27.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 114
  • 5.28 University of Cambridge Company Overview 115
    • 5.28.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 115
  • 5.29 University of Iowa Company Overview 116
    • 5.29.1 University of Iowa Pipeline Products & Ongoing Clinical Trials Overview 116
  • 5.30 Vascular Concepts Ltd Company Overview 117
    • 5.30.1 Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview 117
  • 5.31 Venus MedTech Company Overview 118
    • 5.31.1 Venus MedTech Pipeline Products & Ongoing Clinical Trials Overview 118
  • 5.32 Xeltis AG Company Overview 122
    • 5.32.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 122

6 Transcatheter Aortic Valves (TAVI)- Recent Developments 123

  • 6.1 Oct 26, 2017: HLT to Provide Clinical Update at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) Conference 123
  • 6.2 Oct 26, 2017: MicroPort CardioFlow Attends 2017 PCR London Valves 123
  • 6.3 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 124
  • 6.4 Oct 24, 2017: Admedus TAVR Project on Track with New IP Applications 125
  • 6.5 Oct 24, 2017: Edwards Lifesciences Announces Third Quarter Results 126
  • 6.6 Oct 23, 2017: Boston Scientific Presents Study Results of ACURATE neo Aortic Valve System at Transcatheter Cardiovascular Therapeutics 2017 128
  • 6.7 Oct 23, 2017: Boston Scientific Presents Study Results of Lotus Aortic Valve System at Transcatheter Cardiovascular Therapeutics 2017 128
  • 6.8 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 129
  • 6.9 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 130
  • 6.10 Sep 21, 2017: Medtronic Announces Clinical Study to Evaluate the CoreValve Evolut PRO System in 'Everyday' Clinical Practice 131
  • 6.11 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 132
  • 6.12 Jul 31, 2017: Medtronic Announces CE Mark and European Launch of CoreValve Evolut PRO Transcatheter Valve with Advanced Sealing 134
  • 6.13 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 135
  • 6.14 Jul 10, 2017: Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval 137
  • 6.15 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 138
  • 6.16 Jun 06, 2017: First U.S. Patients Enrolled in an Early Feasibility Study of HLT's New Transcatheter Aortic Valve Replacement System 140
  • 6.17 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 140
  • 6.18 May 17, 2017: Edwards' Novel Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes 143
  • 6.19 May 16, 2017: Real-World Evidence With Edwards SAPIEN 3 Transcatheter Valve Confirms Beneficial Patient Outcomes From Clinical Trials 144
  • 6.20 May 16, 2017: The Boston Scientific LOTUS Valve System Demonstrated Superior Efficacy to CoreValve in Global REPRISE III Trial at One Year 145
  • 6.21 May 16, 2017: New Data on CoreValve and Evolut R Self-Expanding TAVI Systems Show Excellent Clinical Outcomes in Routine Clinical Practice 145
  • 6.22 Apr 28, 2017: Venus Medtech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China English 146
  • 6.23 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 148
  • 6.24 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results 149
  • 6.25 Apr 05, 2017: Aurora Health Care Heart Experts Among First in Nation to Implant New Heart Valve to Treat Aortic Stenosis 150
  • 6.26 Apr 04, 2017: HLT Announces First Patient Enrollments in a Feasibility Study of a New Transcatheter Aortic Valve Replacement System 151
  • 6.27 Mar 22, 2017: Medtronic Receives FDA Approval for CoreValve Evolut Pro Transcatheter Valve with Advanced Sealing 152
  • 6.28 Mar 17, 2017: Landmark SURTAVI Clinical Trial Shows Transcatheter Aortic Valve Replacement with the Self-Expanding Platform Performs as Well as Surgery in Intermediate Risk Severe Aortic Stenosis Patients 153
  • 6.29 Mar 09, 2017: Boston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation 154
  • 6.30 Mar 03, 2017: Colibri Heart Valve Receives ISO 13485 and EN ISO 13485 Certification 155
  • 6.31 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 156
  • 6.32 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 158
  • 6.33 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 159
  • 6.34 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 160
  • 6.35 Jan 17, 2017: Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies 162
  • 6.36 Dec 26, 2016: MicroPort Completes Patient Enrollment of VitaFlow Pre-market Clinical Trial 163
  • 6.37 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 163
  • 6.38 Dec 01, 2016: Medtronic Announces Reimbursement Approval and Launch of CoreValve Evolut R System in Japan 165
  • 6.39 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 166
  • 6.40 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 169
  • 6.41 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 170

7 Appendix 171

  • 7.1 Methodology 171
  • 7.2 About GlobalData 174
  • 7.3 Contact Us 174
  • 7.4 Disclaimer 174

List of Tables

  • Table 1: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development 13
  • Table 2: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Territory 14
  • Table 3: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Regulatory Path 15
  • Table 4: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Estimated Approval Date 16
  • Table 5: Transcatheter Aortic Valves (TAVI) - Ongoing Clinical Trials 17
  • Table 6: Transcatheter Aortic Valves (TAVI) Companies - Pipeline Products by Stage of Development 18
  • Table 7: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development 20
  • Table 8: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 9: Transcatheter Aortic Valve Replacement - Product Status 22
  • Table 10: Transcatheter Aortic Valve Replacement - Product Description 22
  • Table 11: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 12: pTAo-TAVR - Product Status 23
  • Table 13: pTAo-TAVR - Product Description 23
  • Table 14: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 15: Trilogy Aortic Valve System - Product Status 24
  • Table 16: Trilogy Aortic Valve System - Product Description 24
  • Table 17: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 18: ACURATE TAVR - Product Status 26
  • Table 19: ACURATE TAVR - Product Description 26
  • Table 20: Gen 4 Lotus Valve System - Product Status 26
  • Table 21: Gen 4 Lotus Valve System - Product Description 26
  • Table 22: Lotus Edge Sheath 15F - Product Status 27
  • Table 23: Lotus Edge Sheath 15F - Product Description 27
  • Table 24: Lotus Edge Valve System - 21 mm - Product Status 27
  • Table 25: Lotus Edge Valve System - 21 mm - Product Description 28
  • Table 26: Lotus Edge Valve System - 23 mm - Product Status 28
  • Table 27: Lotus Edge Valve System - 23 mm - Product Description 28
  • Table 28: Lotus Edge Valve System - 25 mm - Product Status 29
  • Table 29: Lotus Edge Valve System - 25 mm - Product Description 29
  • Table 30: Lotus Edge Valve System - 27 mm - Product Status 29
  • Table 31: Lotus Edge Valve System - 27 mm - Product Description 30
  • Table 32: Lotus Edge Valve System - 29 mm - Product Status 30
  • Table 33: Lotus Edge Valve System - 29 mm - Product Description 30
  • Table 34: LOTUS Next Gen - Product Status 31
  • Table 35: LOTUS Next Gen - Product Description 31
  • Table 36: Lotus Valve System - 21 mm - Product Status 31
  • Table 37: Lotus Valve System - 21 mm - Product Description 32
  • Table 38: Lotus Valve System - 23 mm - Product Status 32
  • Table 39: Lotus Valve System - 23 mm - Product Description 33
  • Table 40: Lotus Valve System - 25 mm - Product Status 33
  • Table 41: Lotus Valve System - 25 mm - Product Description 34
  • Table 42: Lotus Valve System - 27 mm - Product Status 34
  • Table 43: Lotus Valve System - 27 mm - Product Description 34
  • Table 44: Lotus Valve System - 29 mm - Product Status 35
  • Table 45: Lotus Valve System - 29 mm - Product Description 35
  • Table 46: Boston Scientific Corp - Ongoing Clinical Trials Overview 36
  • Table 47: Lotus Valve System - 23 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 39
  • Table 48: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers 39
  • Table 49: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 39
  • Table 50: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 40
  • Table 51: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 40
  • Table 52: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 40
  • Table 53: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX 41
  • Table 54: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 41
  • Table 55: Lotus Valve System - 27 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 42
  • Table 56: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 42
  • Table 57: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 42
  • Table 58: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 43
  • Table 59: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 43
  • Table 60: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety:REPRISE II FLEX 43
  • Table 61: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 44
  • Table 62: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 44
  • Table 63: Lotus Valve System - 25 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 45
  • Table 64: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 45
  • Table 65: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 45
  • Table 66: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China 46
  • Table 67: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan 46
  • Table 68: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 46
  • Table 69: Lotus Valve System - 21 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 47
  • Table 70: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 47
  • Table 71: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 47
  • Table 72: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 48
  • Table 73: Lotus Valve System - 29 mm - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 49
  • Table 74: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve 49
  • Table 75: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND 49
  • Table 76: Lotus Valve System - 29 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA) 50
  • Table 77: Lotus Edge Valve System - 23 mm - Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation 51
  • Table 78: Lotus Edge Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 51
  • Table 79: Lotus Edge Valve System - 23 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety 51
  • Table 80: Lotus Edge Valve System - 29 mm - Reprise Edge 29 Mm Eu Study: Repositionable Percutaneous Replacement of Native Stenotic Aortic Valve Through Implantation of Lotus Edge 29 Mm Valve - Evaluation of Safety and Performance 52
  • Table 81: Lotus Edge Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 53
  • Table 82: Lotus Edge Valve System - 25 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety 53
  • Table 83: Lotus Edge Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with the Next Generation Delivery System (REPRISE NGDS) 54
  • Table 84: Lotus Edge Valve System - 27 mm - REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety 54
  • Table 85: Clemson University Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 86: Transcatheter Bioprosthetic Heart Valve - Product Status 55
  • Table 87: Transcatheter Bioprosthetic Heart Valve - Product Description 55
  • Table 88: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 89: Colibri Aortic Heart Valve - 24mm - Product Status 56
  • Table 90: Colibri Aortic Heart Valve - 24mm - Product Description 56
  • Table 91: Colibri Aortic Heart Valve - 21mm - Product Status 57
  • Table 92: Colibri Aortic Heart Valve - 21mm - Product Description 57
  • Table 93: Colibri Aortic Heart Valve - 27mm - Product Status 57
  • Table 94: Colibri Aortic Heart Valve - 27mm - Product Description 58
  • Table 95: Colibri TAVI System - Product Status 58
  • Table 96: Colibri TAVI System - Product Description 58
  • Table 97: Delta Aortic Heart Valve - Product Status 59
  • Table 98: Delta Aortic Heart Valve - Product Description 59
  • Table 99: Venibri Transcatheter Heart Valve System - Product Status 59
  • Table 100: Venibri Transcatheter Heart Valve System - Product Description 60
  • Table 101: Daidalos Solutions BV Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 102: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Status 61
  • Table 103: Sutureless Trans-Catheter Aortic Valve Replacement (TAVR) - Product Description 61
  • Table 104: Direct Flow Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 105: 18F Direct Flow Medical Transcatheter Aortic Valve System - Product Status 62
  • Table 106: 18F Direct Flow Medical Transcatheter Aortic Valve System - Product Description 62
  • Table 107: 23mm Direct Flow Medical Transcatheter Aortic Valve System - Product Status 63
  • Table 108: 23mm Direct Flow Medical Transcatheter Aortic Valve System - Product Description 63
  • Table 109: Direct Flow Medical Inc - Ongoing Clinical Trials Overview 64
  • Table 110: 18F Direct Flow Medical Transcatheter Aortic Valve System - A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System for the Treatment of Patients with Severe Aortic Stenosis 65
  • Table 111: 18F Direct Flow Medical Transcatheter Aortic Valve System - SALUS Trial Transcatheter Aortic Valve Replacement System Pivotal Trial the Safety and Effectiveness of the Direct Flow Medical Tanscatheter Aortic Valve System 65
  • Table 112: DSM Dyneema B.V. Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 113: Dyneema Purity - Transcatheter Heart Valve - Product Status 66
  • Table 114: Dyneema Purity - Transcatheter Heart Valve - Product Description 66
  • Table 115: Edwards Lifesciences Corp Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 116: Edwards CENTERA Valve - Product Status 67
  • Table 117: Edwards CENTERA Valve - Product Description 68
  • Table 118: Edwards SAPIEN 3 Transcatheter Heart Valve - Low Risk - Product Status 68
  • Table 119: Edwards SAPIEN 3 Transcatheter Heart Valve - Low Risk - Product Description 68

List of Figures

  • Figure 1: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Stage of Development 13
  • Figure 2: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Territory 14
  • Figure 3: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Regulatory Path 15
  • Figure 4: Transcatheter Aortic Valves (TAVI) - Pipeline Products by Estimated Approval Date 16
  • Figure 5: Transcatheter Aortic Valves (TAVI) - Ongoing Clinical Trials 17
Back to Top